NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Update

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) saw a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 22,600 shares, a drop of 56.4% from the October 15th total of 51,800 shares. Based on an average daily volume of 204,500 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.3% of the shares of the company are sold short.

NLS Pharmaceutics Trading Down 11.3 %

Shares of NLS Pharmaceutics stock traded down $0.44 during trading on Wednesday, reaching $3.46. The company’s stock had a trading volume of 65,997 shares, compared to its average volume of 152,136. The business’s fifty day moving average price is $3.03 and its 200-day moving average price is $1.18. NLS Pharmaceutics has a one year low of $3.15 and a one year high of $29.08.

Institutional Investors Weigh In On NLS Pharmaceutics

A hedge fund recently raised its stake in NLS Pharmaceutics stock. Armistice Capital LLC grew its stake in shares of NLS Pharmaceutics Ltd. (NASDAQ:NLSP) by 6.4% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,311,000 shares of the company’s stock after buying an additional 139,000 shares during the period. Armistice Capital LLC owned approximately 19.62% of NLS Pharmaceutics worth $501,000 as of its most recent filing with the SEC.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).